Extensive calcification in adenocarcinoma of the lung: A case report

por Watanabe, Fumiaki, Adachi, Katsutoshi, Ito, Kentaro, Iwanaka, Soichi, Ohiwa, Ayaka, Sakakura, Yasumasa, Nishimura, Tadashi, Naito, Masahiro
Publicado 2020

Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma

por Nishimura, Tadashi, Fujiwara, Takumi, Fujimoto, Hajime, Tarumi, Hirotoshi, Tsuji, Chikashi, Iwanaka, Soichi, Sakakura, Yasumasa, Naito, Masahiro, Okugawa, Yoshinaga, Yasuma, Taro, Gabazza, Esteban Cesar, Oomoto, Yasuhiro, Kobayashi, Tetsu, Ibata, Hidenori
Publicado 2023

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation...

por Nishimura, Tadashi, Okano, Tomohito, Naito, Masahiro, Iwanaka, Soichi, Ohiwa, Ayaka, Sakakura, Yasumasa, Yasuma, Taro, Fujimoto, Hajime, D'Alessandro‐Gabazza, Corina N., Oomoto, Yasuhiro, Kobayashi, Tetsu, Gabazza, Esteban C., Ibata, Hidenori
Publicado 2021

Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report

por Nishimura, Tadashi, Okano, Tomohito, Naito, Masahiro, Tsuji, Chikashi, Iwanaka, Soichi, Sakakura, Yasumasa, Yasuma, Taro, Fujimoto, Hajime, D'Alessandro-Gabazza, Corina N, Oomoto, Yasuhiro, Kobayashi, Tetsu, Gabazza, Esteban C, Ibata, Hidenori
Publicado 2021

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

por Nishimura, Tadashi, Fujimoto, Hajime, Okano, Tomohito, Naito, Masahiro, Tsuji, Chikashi, Iwanaka, Soichi, Sakakura, Yasumasa, Yasuma, Taro, D’Alessandro-Gabazza, Corina N., Oomoto, Yasuhiro, Gabazza, Esteban C., Kobayashi, Tetsu, Ibata, Hidenori
Publicado 2022